Abstracts tagged "Lupus nephritis"

Abstract Number: 0893 • ACR Convergence 2023
Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Trine Jorgensen and Lindsey Han, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…
Abstract Number: 1457 • ACR Convergence 2023
Obesity Is an Independent Poor Prognostic Factor in Lupus Nephritis
Francy Milena Cuervo Gutiérrez¹, Antoine Enfrein², Frederic Houssiau³ and Farah Tamirou⁴, ¹Fundacion Santa Fe de Bogota, Bogotá, Colombia, ²CHU de Nantes, Nantes, France, ³CUSL - UCLouvain, Brussels, Belgium, ⁴UCLouvain - Cliniques universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: Up to 50% of patients suffering from systemic lupus erythematosus (SLE) develop lupus nephritis (LN) within the first 10 years of diagnosis and 5…
Abstract Number: 1511 • ACR Convergence 2023
B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
Ed Vital¹, Dario Roccatello², David Black³, Rhian Jacob-Moffatt⁴, Cary M. Looney⁵, Elsa Martins⁵, Huiyan (Ashley) Mao³, Thomas Schindler⁶, Himanshi Seghal⁵, Jay Garg⁷, Jorge Ross Terres⁷ and Richard Furie⁸, ¹University of Leeds, Leeds, United Kingdom, ²University of Torino, Torino, Italy, ³Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁷Genentech, Inc., South San Francisco, CA, ⁸Northwell Health, Manhasset, NY
Background/Purpose: Patients with LN who received obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, with standard-of-care (MMF) immunosuppression (Phase II NOBILITY; NCT02550652; PMID 34615636) showed…
Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
Fadi Kharouf¹, Juan Pablo Diaz Martinez², Dafna Gladman³ and Zahi Touma⁴, ¹University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…
Abstract Number: 2589 • ACR Convergence 2023
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Emily Zhang¹, Sarah Capponi², Rebecca Scobell³, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan⁴, Mindy Lo⁴, Olha Halyabar⁵, Melissa Hazen¹, Ezra Cohen⁶, Lauren Henderson¹, Siobhan Case⁷, Margaret Chang¹, Ankana Daga¹, Jonathan Hausmann⁸, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma⁴, Fatma Dedeoglu⁴, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁹, Mary Beth Son⁴ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Hospital of the University of Pennsylvania, New Hope, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Children's Hospital/Boston Medical Center, Newton, MA, ⁶Bmc, Needham, MA, ⁷Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁸Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…
Abstract Number: 0572 • ACR Convergence 2023
Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis
Erdem Gurel¹, Suzan Cinar², Ozge Hurdogan³, Yasemin Ozluk³, Isin Kilicaslan⁴, Sibel Varelci¹, Safak Mirioglu⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Lale Ocal¹, Murat Inanc⁶ and Bahar Artim-Esen⁶, ¹Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ²Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbıl, Turkey, ⁵Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: CD163 is a glycosylated membrane protein expressed in monocytes and macrophages that phagocytize the hemoglobin/haptoglobin complex. As a result of proinflammatory stimuli, CD163 is…
Abstract Number: 0896 • ACR Convergence 2023
Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus
Atsushi Manno¹, Tomohiro Honda¹, Chiharu Kuwata², Shiho Ito², Michinori Kadokura¹, Reiko Mizutani³, Shinnosuke Yamada¹ and Yoshiaki Tomimori¹, ¹Daiichi Sankyo Co., Ltd., Shinagawa-ku, Japan, ²Daiichi Sankyo Co., Ltd., Edogawa-ku, Japan, ³Daiichi Sankyo RD Novare Co., Ltd., Edogawa-ku, Japan
Background/Purpose: The centrality of Toll-like receptor 7 (TLR7) to the pathogenesis of systemic lupus erythematosus (SLE) was recently underscored by a report that high TLR7…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1579 • ACR Convergence 2023
Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Natalie McCormick¹, Chio Yokose¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2) have benefits on kidney and cardiovascular (CV) outcomes that are largely independent of glycemic control. These benefits have been demonstrated…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 0577 • ACR Convergence 2023
Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis
Michelle Patricia Loeza-Uribe¹, Michelle Nicolle Espinoza-Carranza¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, Nancy Raquel Mejía-Domínguez², Guillermo Juárez-Vega², José Luis Maravillas-Montero², Karina Santana-de Anda¹, José Jiram Torres-Ruiz¹ and Diana Gómez-Martín¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Mexico
Background/Purpose: Intrinsic signaling of intracytoplasmic TLRs (7 and 9) and MyD88 in B cells (BC) plays an important role in the development and pathogenesis of…
Abstract Number: 0899 • ACR Convergence 2023
Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, John Greally², Masako Suzuki³, Jee-Young Moon², Tao Wang², Yvonne M Saenger², Brad Rovin⁴ and J. Michelle Kahlenberg⁵, ¹Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Texas A&M University, College Station, TX, ⁴Ohio State University, Columbus, OH, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Tubulointerstitial injury is a strong predictor of progression to kidney failure in lupus nephritis (LN). Prior animal studies suggest intrarenal complement activation has an…
Abstract Number: 1464 • ACR Convergence 2023
Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Omer Pamuk¹, Ansaam Daoud², Loai Dweik³, Niraj Desai⁴ and sarfaraz Hasni⁵, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals, Case Western Reserve University, Akron, OH, ³Cleveland Clinic Akron General, Akron, OH, ⁴Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: End-stage renal disease (ESRD) may develop in up to 20% of patients with lupus nephritis (LN). The SLE disease activity generally declines after the…
Abstract Number: 1585 • ACR Convergence 2023
Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure
Angelique Cortez¹, Lindsay Mendyka², Fred Kolling³, Michael Whitfield¹ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Dartmouth-Hitchcock, Lebanon, NH
Background/Purpose: Lupus (SLE) is one of the leading causes of death in young women in the United States. Roughly ~80% of SLE patients experience sensitivity…
Abstract Number: 2310 • ACR Convergence 2023
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Renal flares in patients with SLE result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated to…

« Previous Page
1
…
8
9
10
11
12
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.